Beneficial effects of Lactobacillus rhamnosus hsryfm 1301 fermented milk on rats with nonalcoholic fatty liver disease

Chen, Fan; Liang, Yonghui; Liang, Jiaojiao; Shen, Feifei; Cheng, Ya; Qu, Hengxian; Wa, Yunchao; Guo, Congcong; Gu, Ruixia; Qian, Jian‐Ya; Chen, Xia; Zhang, Chenchen; Guan, Chengran

doi:10.3168/jds.2022-22383

Cited by 6 publications

(4 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liver injury can lead to impaired ammonia metabolism in the body, potentially resulting in hyperammonemia ( Jimenez-Torres et al, 2021 ); however, a decrease in glutamate can reverse this condition. Moreover, low levels of glutamate are beneficial for ROS clearance and the improvement of antioxidant capacity ( Demircan et al, 2014 ; Chen et al, 2023 ). The excessive oxidation of fatty acids can increase the end-product acetate and induce the accumulation of ketone bodies in the CCl 4 -induced ALI model ( Huo et al, 2016 ), which are consistent with our results of increasing acetic acid and ketone body 3HB in CCl 4 group.…”

Section: Discussionmentioning

confidence: 99%

Integrated network analysis and metabolomics reveal the molecular mechanism of Yinchen Sini decoction in CCl4-induced acute liver injury

Zheng,

Shi,

Meng

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Objective: Yinchen Sini decoction (YCSND), a traditional Chinese medicine (TCM) formula, plays a crucial role in the treatment of liver disease. However, the bioactive constituents and pharmacological mechanisms of action remain unclear. The present study aimed to reveal the molecular mechanism of YCSND in the treatment of acute liver injury (ALI) using integrated network analysis and metabolomics.Methods: Ultra-high-performance liquid chromatography coupled with Q-Exactive focus mass spectrum (UHPLC-QE-MS) was utilized to identify metabolites in YCSND, and high-performance liquid chromatography (HPLC) was applied to evaluate the quality of four botanical drugs in YCSND. Cell damage and ALI models in mice were established using CCl4. 1H-NMR metabolomics approach, along with histopathological observation using hematoxylin and eosin (H&E), biochemical measurements, and reverse transcription quantitative real-time PCR (RT-qPCR), was applied to evaluate the effect of YCSND on CCl4- induced ALI. Network analysis was conducted to predict the potential targets of YCSND in ALI.Result: Our results showed that 89 metabolites in YCSND were identified using UHPLC-QE-MS. YCSND protected against ALI by reducing the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and malondialdehyde (MDA) contents and increasing those of superoxide dismutase (SOD), and glutathione (GSH) both in vivo and in vitro. The 1H-NMRmetabolic pattern revealed that YCSND reversed CCl4-induced metabolic abnormalities in the liver. Additionally, the Kyoto Encyclopedia of Genes and Genome (KEGG) pathway enrichment analysis identified five pathways related to liver injury, including the PI3K-AKT, MAPK, HIF-1, apoptosis, and TNF signaling pathways. Moreover, RT-qPCR showed YCSND regulated the inflammatory response (Tlr4, Il6, Tnfα, Nfκb1, Ptgs2, and Mmp9) and apoptosis (Bcl2, Caspase3, Bax, and Mapk3), and inhibited PI3K-AKT signaling pathway (Pi3k and Akt1). Combined network analysis and metabolomics showed a link between the key targets (Tlr4, Ptgs2, and Mmp9) and vital metabolites (choline, xanthine, lactate, and 3-hydroxybutyric acid) of YCSND in ALI.Conclusion: Overall, the results contribute to the understanding of the therapeutic effects of YCSND on ALI, and indicate that the integrated network analysis and metabolomics could be a powerful strategy to reveal the pharmacological effects of TCM.

show abstract

Section: Discussionmentioning

confidence: 99%

Integrated network analysis and metabolomics reveal the molecular mechanism of Yinchen Sini decoction in CCl4-induced acute liver injury

Zheng,

Shi,

Meng

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Lactobacillus isolates reported to alleviate MAFLD include L. reuteri [ 120 ], L. plantarum [ 116 - 118 ], L. pentosus [ 119 ], L. rhamnosus [ 121 ], L. paracasei [ 114 , 115 ], L. gasseri [ 113 ], and Latilactobacillus sakei [ 122 ]. Generally, these isolates demonstrate the capability to reduce hepatic fat accumulation, suppress immune activation and improve intestinal barrier integrity.…”

Section: Icrobial Metabolites On Metabolic-associated Fatty Liver Dis...mentioning

confidence: 99%

Roles of gut microbes in metabolic-associated fatty liver disease

Chen

2023

Tzu Chi Medical Journal

View full text Add to dashboard Cite

Metabolic-associated fatty liver disease (MAFLD) is the most common chronic liver disease. Gut dysbiosis is considered a significant contributing factor in disease development. Increased intestinal permeability can be induced by gut dysbiosis, followed by the entry of lipopolysaccharide into circulation to reach peripheral tissue and result in chronic inflammation. We reviewed how microbial metabolites push host physiology toward MAFLD, including short-chain fatty acids (SCFAs), bile acids, and tryptophan metabolites. The effects of SCFAs are generally reported as anti-inflammatory and can improve intestinal barrier function and restore gut microbiota. Gut microbes can influence intestinal barrier function through SCFAs produced by fermentative bacteria, especially butyrate and propionate producers. This is achieved through the activation of free fatty acid sensing receptors. Bile is directly involved in lipid absorption. Gut microbes can alter bile acid composition by bile salt hydrolase-producing bacteria and bacterial hydroxysteroid dehydrogenase-producing bacteria. These bile acids can affect host physiology by activating farnesoid X receptor Takeda G protein-coupled receptor 5. Gut microbes can also induce MAFLD-associated symptoms by producing tryptophan metabolites kynurenine, serotonin, and indole-3-propionate. A summary of bacterial genera involved in SCFAs production, bile acid transformation, and tryptophan metabolism is provided. Many bacteria have demonstrated efficacy in alleviating MAFLD in animal models and are potential therapeutic candidates for MAFLD.

show abstract

“…Lacticaseibacillus rhamnosus (hsryfm1301, LR5957, LR5897, and B10) fermented yogurt may reduce high-fat diet-induced obesity and regulate obesity-induced dyslipidemia and hepatic lipid accumulation. [21][22][23] In one study, it was found that a single-strain fermented yogurt made with Lacticaseibacillus rhamnosus LV108 was more effective than probiotic combined fermented yogurt in regulating gene expression related to hepatic lipid metabolism, and in reducing visceral lipid accumulation in hyperlipidemic rats. 24 In conclusion, these research findings support that yogurt may significantly improve metabolic disorders induced by high-fat diet by regulating the gut microbiota and lipid metabolism.…”

Section: Introductionmentioning

confidence: 99%

Lacticaseibacillus rhamnosus HF01 fermented yogurt alleviated high-fat diet-induced obesity and hepatic steatosis via the gut microbiota–butyric acid–hepatic lipid metabolism axis

Sun,

Liu,

Wang

et al. 2024

Food Funct.

View full text Add to dashboard Cite

show abstract

Beneficial effects of Lactobacillus rhamnosus hsryfm 1301 fermented milk on rats with nonalcoholic fatty liver disease

Cited by 6 publications

References 81 publications

Integrated network analysis and metabolomics reveal the molecular mechanism of Yinchen Sini decoction in CCl4-induced acute liver injury

Integrated network analysis and metabolomics reveal the molecular mechanism of Yinchen Sini decoction in CCl4-induced acute liver injury

Roles of gut microbes in metabolic-associated fatty liver disease

Lacticaseibacillus rhamnosus HF01 fermented yogurt alleviated high-fat diet-induced obesity and hepatic steatosis via the gut microbiota–butyric acid–hepatic lipid metabolism axis

Contact Info

Product

Resources

About